Sort
48,018 grants matching “immunotherapy”
Parkin tumor suppression
$499,626Dario C. Altieri · Wistar Institute · R01 · FY2024 · CA
Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas
$499,609Weizhou Zhang · University Of Florida · R01 · FY2025 · CA
OVARIAN CANCER IMMUNOTHERAPY USING REDIRECTED ENDOGENOUS ANTI-GAL ANTIBODY
$499,574University Of Wisconsin System · · FY2008 · Department of Defense
Project 3
$499,545Dimitrios P Kontoyiannis · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · P01 · FY2025 · AI
Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach
$499,533Susan A Gauthier · Weill Medical Coll Of Cornell Univ · R01 · FY2018 · NS
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells
$499,514John H Sampson · Duke University · R01 · FY2016 · CA
Center for Cancer Immunology and Immunotherapy (CCII) - Functional Immunomics Core (FIC)
$499,422Haribabu Bodduluri · University Of Louisville · P20 · FY2025 · GM
Role of TIEG1 in Foxp3+Treg development and tumor progression
$499,405Venuprasad K Poojary · Wayne State University · RC1 · FY2009 · CA
Targeted Gene Delivery and Human Dendritic Cell Maturation Through a Novel Hybrid Biological-Biomaterial Vector System
$499,389Blaine A. Pfeifer · State University Of New York At Buffalo · R01 · FY2023 · CA
Allergen T cell epitopes and phenotypes in peanut allergy
$499,348William W. Kwok · Benaroya Research Inst At Virginia Mason · U19 · FY2022 · AI
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCC's
$499,311Sana D Karam · Washington University · R01 · FY2025 · DE
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
$499,263J. Silvio Gutkind · University Of California, San Diego · R01 · FY2021 · CA
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.
$499,261Alexander H. Stegh · Washington University · R01 · FY2023 · NS
Targeting lymph node metastases to block cancer progression
$499,258Timothy P Padera · Massachusetts General Hospital · R01 · FY2023 · CA
Targeting lymph node metastases to block cancer progression
$499,258Timothy P Padera · Massachusetts General Hospital · R01 · FY2025 · CA
Tumor-Targeted STING Agonism in Head and Neck Squamous Cell Carcinoma
$499,238Thomas Hayman · Yale University · R37 · FY2025 · CA
Role of AMPK in melanoma brain metastasis
$499,166Bin Zheng · Massachusetts General Hospital · R01 · FY2023 · CA
Transcriptional and metabolic regulation of Treg cell specification for the control of allergic airway disease
$499,162Kai Yang · Indiana University Indianapolis · R01 · FY2024 · AI
BCL11B activation as an approach for enhancing the efficacy of immunotherapy
$499,162Chintan Parekh · Children'S Hospital Of Los Angeles · R01 · FY2023 · AI
Temporal Biomarker-Powered Immunotherapy Targeting GFAP for Traumatic Brain Injury
$499,065William E Haskins · Gryphon Bio, Inc. · R44 · FY2021 · NS
TLI and ATG Conditioning for Combined Kidney and Blood Stem Cell Transplantation
$499,054Samuel Strober · Stanford University · P01 · FY2016 · HL
Ultrasound imaging and enhanced therapeutic response
$499,000Katherine W Ferrara · University Of California At Davis · R01 · FY2017 · CA
Ultrasound imaging and enhanced therapeutic response
$499,000Katherine W Ferrara · University Of California At Davis · R01 · FY2016 · CA
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation
$498,982Benjamin G Vincent · Univ Of North Carolina Chapel Hill · R37 · FY2024 · CA
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma
$498,957Cassian Yee · University Of Tx Md Anderson Can Ctr · P50 · FY2020 · CA